Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Rapid Response Innovation Awards, 2008
    Generating Patient-Specific Induced Pluripotent Stem Cells to Study Parkinson's Disease

    Objective/Rationale:
    One of the major hurdles for Parkinson’s research is the lack of live dopamine neurons from patients for long-term studies and drug screens. This project will use the newly...

  • Rapid Response Innovation Awards, 2008
    Posiphen as a Well-tolerated Alpha-synuclein Inhibitor and a Potential 5'UTR Directed Drug Treatment of Parkinson's Disease

    Objective/Rationale:
    An inter-relationship exists between the Parkinson’s disease-related protein alpha-synuclein and the Alzheimer’s Aß-amyloid plaque protein. Phenserine reached clinical assessment...

  • Rapid Response Innovation Awards, 2008
    The Role of the Unfolded Protein Response (UPR) in Parkinson's Disease

    Objective/Rationale:
    Our general objective is to investigate the role of the cellular stress responses linked to organelle damage such as the Unfolded Protein Response in the development of Parkinson...

  • Rapid Response Innovation Awards, 2008
    A Novel Cell Model for LRRK2 Parkinson's Disease

    Objective/Rationale:
    The aim of this project is to create a model of Parkinson’s disease using skin cells from  patients who have an inherited form of Parkinson’s disease. Using newly developed stem...

  • Rapid Response Innovation Awards, 2008
    Identification of binding proteins for alpha-synuclein oligomers in brain and cells

    Mutations in the PARK-1 and PARK-4 genes leads to alpha-synuclein aggregation with pathology eventually resembling that of sporadic PD. One question is whether the insoluble form of alpha-synuclein is...

  • Rapid Response Innovation Awards, 2008
    The Glucosylceramide Pathway in Parkinson's Disease and other Synucleinopathies: Genetic defects, Neuropathological characterization and cell culture models

    Objective/Rationale: 
    Mutations in the beta glucocerebrosidase (GBA) gene are associated with Parkinson’s disease. Only a small number of neuropathologically confirmed PD, multiple system atrophy (MSA)...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.